Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT05399498
PHASE2
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
Sponsor: University of Chicago
View on ClinicalTrials.gov
Summary
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
Official title: An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2023-11-01
Completion Date
2025-12-01
Last Updated
2026-10-29
Healthy Volunteers
No
Interventions
DRUG
Psilocybin
Psilocybin 25mg capsule
Locations (1)
University of Chicago
Chicago, Illinois, United States